Fibrobiologics announced preliminary proof-of-concept results for its fibroblast-based therapeutic approach to treating type 1 diabetes. According to the company, early preclinical data showed a reduction in blood glucose levels following the administration of fibroblasts in diabetic models.
The company said the therapy is designed to leverage fibroblasts’ regenerative and immunomodulatory properties to support pancreatic function and potentially protect insulin-producing cells. Fibrobiologics claims this strategy may offer an alternative to existing treatments by directly targeting disease mechanisms.
According to the company, the research is still in its early stages and further studies are planned to better understand the treatment’s efficacy, durability and safety profile. Fibrobiologics said it aims to refine dosing strategies and explore how fibroblast therapy might complement or replace current insulin-dependent regimens.
The company claims the data supports continued development of its broader pipeline, which targets chronic conditions using fibroblast-based cell therapies. Fibrobiologics said it remains focused on advancing this program into more advanced preclinical testing, with the goal of eventually reaching clinical trials for patients with type 1 diabetes.
Fibrobiologics noted its broader research strategy seeks to harness the therapeutic potential of fibroblasts across multiple disease areas where regeneration and immune modulation could address significant unmet needs.
